Ketamine vs Antidepressants: What's Actually Different (2026)

"Should I try ketamine instead of antidepressants?" is one of the most common questions in this field, and it contains a misunderstanding worth clearing up before any comparison: in European medicine, ketamine enters the picture after antidepressants have been properly tried, and the EU-approved form is taken together with one; whether any ketamine regimen fits your treatment is a specialist decision, never a self-directed swap. This page puts the two side by side (mechanism, speed, durability, evidence, cost, access), so the conversation you have with your clinician starts from facts rather than headlines. If you are at the stage where antidepressants have already failed, the full map of options is in depression treatment isn't working.

Two different mechanisms, two different clocks

Antidepressants (SSRIs, SNRIs and their relatives) act on the brain's monoamine systems, chiefly serotonin and noradrenaline. Their clinical rhythm is familiar: a low starting dose, an effect that builds over two to six weeks, dose adjustments, and, when they work, continuation for months to prevent relapse (NICE NG222). Their average effect across trials is real and moderate, and it varies from person to person; a large share of people respond well to the first or second drug tried, which is exactly why the guidelines put them first.

Ketamine is a dissociative anaesthetic acting principally on the NMDA glutamate receptors: a different pharmacology from conventional oral antidepressants, though its antidepressant mechanism is not fully understood. The different target is why it can act within days rather than weeks and why it is studied in people for whom standard drugs have not worked; it does not by itself establish superior effectiveness or predict who will respond. Racemic ketamine, given as an intravenous infusion under monitoring, produces a rapid antidepressant effect that small controlled trials have shown consistently since 2006 (Zarate et al. 2006; Caddy et al. 2015, Cochrane). It has never been through regulatory approval as an antidepressant, so its use for depression is off-label: legal, but outside its licensed indication. Its close relative, esketamine nasal spray (Spravato), is an approved EU medicine for treatment-resistant depression: the two routes are compared in detail in Spravato vs ketamine infusions.

Speed: the real difference, and its limits

The single fact that made ketamine famous in psychiatry is genuine: relief can arrive within hours to a day of an infusion. The foundational trial deserves its exact numbers: 18 medication-free patients enrolled, 17 received ketamine, and 71% met response criteria the next day (Zarate et al. 2006). Response is not remission, a small selected trial does not predict routine outcomes, and the study did not compare ketamine against an ongoing oral-antidepressant course; what it established is the speed signal that later trials kept reproducing. Conventional antidepressants cannot do this; their two-to-six-week onset is one of the hardest parts of depression treatment, because it asks the most patience of people who have the least to spare.

But speed is only half the clock. The benefit of a single ketamine infusion usually fades within one to two weeks, repeated infusions are needed to maintain it, and relapse after stopping is common (Marcantoni et al. 2020). A conventional antidepressant that works has the opposite profile: slow to start, but designed to hold; guidelines recommend continuing for months after recovery precisely because the maintained effect is the point (NICE NG222). One fairness note on this comparison: a fading single dose against continuing daily treatment compares acute with maintenance. Compared properly, both sides have continuation strategies: esketamine has a defined maintenance regimen within its label, and IV ketamine continuation is individualised, with regular review of benefit, harms and stopping criteria, on a thinner evidence base than oral maintenance. Fast-but-fading versus slow-but-holding remains the one-line summary for single treatments, and it is why the two are increasingly discussed as complements rather than rivals.

Where each belongs in European treatment

The guideline position is worth stating carefully rather than loudly. For moderate to severe depression, conventional antidepressants, alongside psychological therapy, are the standard medication route in the guidelines we cite, chosen with severity and your informed preference in play; for less severe depression, NICE explicitly does not reach for medication first unless that is your preference (NICE NG222), and we cite specific guidelines rather than claiming every European system reads identically. Nothing about ketamine changes that architecture. Esketamine's treatment-resistant indication enters at a defined later point, conventionally at least two adequate antidepressant courses that have not helped in the current episode. That is not bureaucratic gatekeeping; it reflects the evidence. Most people with depression never need anything beyond the standard options, the standard options are vastly better studied, and the rapid-acting routes carry their own burdens, supervised clinic sessions, monitoring, off-label status or strict reimbursement criteria.

Esketamine's EU label encodes this position precisely: it is authorised "in combination with an SSRI or SNRI, indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode" (EMA EPAR). Note both halves for that indication: after two failed antidepressants, and in combination with one. The same label contains a second, separate indication: short-term treatment, with an oral antidepressant, for rapid reduction of depressive symptoms in a psychiatric emergency, which does not impose the two-failure criterion. And one safety line belongs beside it: rapid symptom reduction does not establish suicide prevention and does not remove the need for hospital-level care where that is indicated. The full trial record, including its mixed results and the suicidality question, is in our esketamine evidence review.

"Can ketamine replace my antidepressant?"

The honest answer has become more nuanced than a flat no, and the practical rule has not changed at all: do not stop or replace prescribed medication without specialist review. The regulatory picture now differs by region: the EU authorises esketamine in combination with an oral antidepressant, while the US FDA has approved esketamine monotherapy for adult treatment-resistant depression (FDA prescribing information); IV racemic ketamine sits outside both labels. None of this proves long-term interchangeability: no trials establish ketamine or esketamine as a long-term replacement for oral antidepressant treatment across maintenance horizons, long-term repeated ketamine carries documented risks reviewed in our ketamine evidence review (with the heavy-exposure versus supervised-treatment distinction that section explains), and in Europe the reimbursed pathway is the combination one. What the evidence supports today: rapid, supervised help at the treatment-resistant stage, usually layered onto ongoing care, with continuation reviewed rather than presumed. If you want to stop an antidepressant (because of side effects, or because it is not working), that is a legitimate conversation to have with your prescriber about switching, tapering (which is individualised, never abrupt) or augmenting (the options ladder), and persistent side effects or lack of response are reasons for review, not for waiting longer or raising doses on your own.

What a proper ketamine assessment covers

Before any first dose, a defensible service assesses the diagnosis itself, bipolar or psychotic symptoms, suicide risk, substance use and medical comorbidity, and reviews your medicines and alcohol use, with particular care around opioids, benzodiazepines and other sedatives; SSRIs and SNRIs can usually continue, confirmed individually rather than assumed. An online questionnaire, including our own eligibility check, cannot establish diagnosis or prescribing safety: it orients, the prescriber decides. During sessions, monitoring covers blood pressure, pulse, oxygen saturation and consciousness, with staff able to manage deterioration, followed by recovery assessment, discharge instructions and transport home. One more model question worth asking before you compare prices: does the fee buy an infusion only, or a programme with preparation, psychological support and integration? Both models exist, their costs differ for structural reasons, and neither a higher price nor a bigger therapy package is by itself proof of better outcomes (CANMAT recommendations).

Cost and access: the stark asymmetry

Antidepressants are among the cheapest medicines in existence: generic SSRIs cost cents per day and are reimbursed by every European health system, prescribed in any GP surgery. The rapid-acting routes run on entirely different economics. IV ketamine for depression is a largely private market, and prices are package prices, so we quote named providers rather than invented averages: Oxford Health lists £265 per infusion with a separate £265 assessment; Save Minds lists £990 for a first session and £595 for subsequent ones; published German fees run roughly €200 to 400 per session (cost guide). Those are different service packages (assessment, monitoring, any psychotherapy component and follow-up are bundled differently), so the honest comparison is the whole course: assessment plus sessions plus reviews plus likely continuation, not one fee multiplied by six. Public funding is uncommon; Norway is the notable exception, funding IV ketamine in public specialist services since August 2025, under registry follow-up and defined conditions. Esketamine rides the approved medicine's rails instead, with three separate questions in every country: is it licensed (EU-wide, yes), is it reimbursed (Germany, Spain, Poland and Scotland among the systems with working routes; England is the cautionary example, where NICE TA854 declined routine funding), and does a service near you actually deliver it, since limited local capacity constrains access even where funding exists (where in Europe). Whether you qualify is checkable: our eligibility check walks the criteria country by country.

Frequently asked questions

Is ketamine better than antidepressants?

Wrong axis. Ketamine is faster; conventional antidepressants are better studied, cheaper, easier to access and built for maintenance. For most people with moderate to severe depression, standard treatment (medication and/or psychological therapy, chosen with severity and preference) works well enough that ketamine never comes up. Ketamine's place is at the treatment-resistant stage: rapid help when standard drugs have failed, usually added to ongoing care, with any change to your existing medication made by a prescriber.

Can I take ketamine while on an SSRI?

In the approved pathway you must: esketamine is authorised only in combination with an SSRI or SNRI, and trial protocols for IV ketamine typically continue existing antidepressants too. Unlike the classic psychedelics, ketamine's antidepressant effect does not require stopping serotonergic medication. Specific combinations and interactions are for your prescriber to assess: bring your full medication list.

How quickly does each one work?

Antidepressants: full benefits build over two to six weeks, with early improvement often visible within one to two weeks and dose adjustments often needed; if nothing at all improves early, that is a reason for review, not for waiting in silence. Ketamine: within hours to a day of an infusion in many patients, and the benefit of a single infusion usually fades within one to two weeks, which is why treatment runs in series with planned review, and why the speed advantage does not settle the comparison on its own.

Why would anyone choose the slow option?

Because slow-but-holding suits a long-term illness, and because the slow option is approved, reimbursed, prescribable by your GP and backed by decades of evidence. Wanting something faster after real suffering is not a misunderstanding of treatment; it is a preference that belongs in the consultation. The realistic question is rarely either/or: it is whether, after standard treatment has genuinely been tried, adding a rapid-acting option is worth its costs and burdens, a decision to make together with a specialist, mapped in our options guide.

Where do I start if antidepressants haven't worked?

With the record, then the country. Write down every antidepressant you have tried: name, highest dose, duration, result; two adequate failed courses in the current episode is the key that opens the treatment-resistant doors, including reimbursed esketamine in much of Europe. Then check your country's actual routes: our eligibility check and country guides map them, and the directory lists verified providers.

Sources

1. NICE NG222 — depression in adults: treatment and management
2. EMA: Spravato (esketamine) — medicine overview and EPAR
3. Zarate et al. (2006), Archives of General Psychiatry — single-infusion ketamine in treatment-resistant depression
4. Caddy et al. (2015), Cochrane Database of Systematic Reviews — ketamine and other glutamate receptor modulators for depression
5. Marcantoni et al. (2020), Journal of Affective Disorders — meta-analysis of IV ketamine for treatment-resistant depression
6. Spravato SmPC — product information, sections 4.1 and 4.7
7. FDA — Spravato prescribing information (US label incl. monotherapy for TRD)
8. Swainson et al. (2021), CANMAT — recommendations on ketamine use in depression
9. NICE TA854 — esketamine for treatment-resistant depression (not recommended for routine use in England)
10. Oxford Health NHS FT — ketamine treatment pathway and published fees
11. Save Minds — published fees

---

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Never stop or change an antidepressant without medical supervision: discontinuation needs planning with your prescriber. Discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.